drugset / Trial / NCT01928888

Placebo Controlled Phase IV Study to Compare the Efficacy and Safety of a Single Dose of Oral Talcid, a Single Dose of Oral Famotidine and a Single Dose of Placebo in Patients With Acute Heartburn Episodes

NCT01928888

Phase 4 Completed 559 enrolled Bayer
RandomizedCrossoverTriple-blindTreatment

Summary

The purpose of this study is to compare the efficacy and safety of a single oral administration of 1000 mg Talcid® (study medication), a single oral administration of 10 mg famotidine and a single oral administration of placebo (comparator without an active substance) in treating the symptoms of acute heartburn episodes. The study is designed to collect more efficacy data on Talcid® in patients using self-medication to relief the symptoms of acute heartburn.

Timeline

Start
2003-05
Primary completion
2004-02
Completion
2004-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Famotidine Other / unclassified 10 mg Oral
Subject HYDROTALCITE ANHYDROUS Small molecule 1000 mg Oral

Indications